Company intelligence / Profile preview
CinRx Pharma
Cincinnati, Ohio, United Statescinrx.com ↗
- Ownership
- Private
- Employees
- ~22
- Development stage
- Other
01
Overview
CinRx has a portfolio of companies (CinCos) with various programs in development. CinCor Pharma (now acquired by AstraZeneca) developed baxdrostat for hypertension. CinFina Pharma is developing obesity therapeutics with CIN-110 (PYY analog) in Phase 1 and CIN-109 (GDF-15 molecule) preparing for Phase 2. The company also has two Phase 2 gastrointestinal programs and several pre-clinical programs[3].
- Therapeutic areas
- GastroenterologyCardiovascularMetabolic DisordersEndocrinologyOncology
- Modalities
- Small molecules (baxdrostat/CIN-107)PYY analog (CIN-110)GDF-15 molecule (CIN-109)dual-agonists (CIN-209, CIN-210)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Roche (licensed baxdrostat/CIN-107)Janssen Pharmaceuticals (licensed obesity therapies)strategic CRO partnership
Beyond the preview
Go deeper on CinRx Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CinRx Pharma.